MyAmyloidosisTeam

How is amyloidosis staged and what tests determine the stage of disease?

Amyloidosis staging depends on which type you have, as different types affect organs differently. Staging helps your care team understand how advanced the disease is and guides treatment decisions.

For AL amyloidosis (the most common type), staging Show Full Answer

How is amyloidosis staged and what tests determine the stage of disease?

Amyloidosis staging depends on which type you have, as different types affect organs differently. Staging helps your care team understand how advanced the disease is and guides treatment decisions.

For AL amyloidosis (the most common type), staging primarily focuses on heart and kidney damage using biomarkers—substances in your blood or urine that show how well your organs are working.

The Mayo Clinic Staging System is commonly used and measures three biomarkers:

- NT-proBNP (N-terminal pro-B-type natriuretic peptide): Shows heart stress or pumping problems
- Cardiac troponin T (cTnT): Indicates heart muscle cell damage
- dFLC (difference between involved and uninvolved free light chains): Measures abnormal amyloid proteins

Your stage (1-4) is determined by how many biomarkers are elevated above specific cutoffs. Stage 1 means all biomarkers are normal, while Stage 4 means all three are elevated.

For kidney staging, doctors look at proteinuria (protein in urine) and kidney function tests to assess damage.

For AA amyloidosis, staging considers factors like age, kidney function (eGFR), and heart biomarkers (NT-proBNP or BNP).

Your doctor may retest these biomarkers during treatment to see if the disease is stable, improving, or progressing.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Stages of Amyloidosis: Breakdown by Type and More

AL Amyloidosis Stages: Progression From Stage 1 to 4